- Home
- LENZ vs NRIX Comparison
LENZ vs NRIX Comparison
Compare LENZ & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- NRIX
- Stock Information
- Founded
- LENZ 2019
- NRIX 2009
- Country
- LENZ United States
- NRIX United States
- Employees
- LENZ N/A
- NRIX N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- NRIX Health Care
- Exchange
- LENZ Nasdaq
- NRIX Nasdaq
- Market Cap
- LENZ 852.0M
- NRIX 750.4M
- IPO Year
- LENZ 2021
- NRIX 2020
- Fundamental
- Price
- LENZ $31.63
- NRIX $17.11
- Analyst Decision
- LENZ Strong Buy
- NRIX Strong Buy
- Analyst Count
- LENZ 4
- NRIX 14
- Target Price
- LENZ $56.25
- NRIX $26.50
- AVG Volume (30 Days)
- LENZ 1.3M
- NRIX 1.7M
- Earning Date
- LENZ 11-05-2025
- NRIX 10-09-2025
- Dividend Yield
- LENZ N/A
- NRIX N/A
- EPS Growth
- LENZ N/A
- NRIX N/A
- EPS
- LENZ N/A
- NRIX N/A
- Revenue
- LENZ $17,500,000.00
- NRIX $83,687,000.00
- Revenue This Year
- LENZ N/A
- NRIX $58.48
- Revenue Next Year
- LENZ $285.82
- NRIX N/A
- P/E Ratio
- LENZ N/A
- NRIX N/A
- Revenue Growth
- LENZ N/A
- NRIX 48.32
- 52 Week Low
- LENZ $16.54
- NRIX $8.18
- 52 Week High
- LENZ $50.40
- NRIX $23.00
- Technical
- Relative Strength Index (RSI)
- LENZ 55.37
- NRIX 80.70
- Support Level
- LENZ $27.44
- NRIX $12.43
- Resistance Level
- LENZ $26.81
- NRIX $13.43
- Average True Range (ATR)
- LENZ 2.41
- NRIX 1.00
- MACD
- LENZ 1.12
- NRIX 0.40
- Stochastic Oscillator
- LENZ 99.43
- NRIX 90.64
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.